Examining gene expression differences in HPV-positive and negative head and neck cancers
Assessment of Genomic Alterations and Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers
This study is trying to see how the genes in HPV-positive and HPV-negative head and neck cancers are different to help find better and less invasive treatments for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche Academic / other |
| Locations | 1 site (Marseille) |
| Trial ID | NCT06133790 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the differences in gene expression between HPV-positive and HPV-negative squamous cell carcinomas of the head and neck. It focuses on identifying predictive markers that could lead to more effective and less invasive treatment options for patients with these cancers. The study will utilize techniques such as PCR, immunohistochemistry, and immunolabelling to analyze tumor samples. By understanding the molecular differences, the research seeks to improve treatment strategies tailored to the specific cancer type.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with histologically proven oropharyngeal or oral cavity squamous cell carcinoma.
Not a fit: Patients with head and neck cancers other than oropharyngeal or oral cavity squamous cell carcinomas may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with head and neck cancers.
How similar studies have performed: While some studies have explored gene expression in head and neck cancers, this specific focus on HPV-related differences is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with oropharyngeal squamous cell carcinoma or the oral cavity histologically proven. * Primary tumor for which a biopsy or excision is required available and sufficient to carry out molecular analysis Exclusion Criteria: - Patient with Head and Neck cancer other than oropharyngeal or oral cavity squamous cells carcinomas
Where this trial is running
Marseille
- Hôpital Privé Clairval — Marseille, France (Recruiting)
Study contacts
- Principal investigator: Jérôme PARIS, MD — Hôpital privé de Clairval
- Study coordinator: Jérôme PARIS, MD
- Email: j.paris@me.com
- Phone: + 33 4 91 17 17 70
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.